[EN] PYRAZOLE CARBOXAMIDE COMPOUNDS FOR USE IN THE TREAMENT OF DISORDERS MEDIATED BY BRUTON'S TYROSINE KINASE (BTK) [FR] COMPOSÉS DE PYRAZOLE-CARBOXAMIDE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LA TYROSINE KINASE DE BRUTON (BTK)
This application discloses compounds according to generic Formula I:
wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
[EN] INHIBITORS OF JANUS KINASES<br/>[FR] INHIBITEURS DE JANUS KINASES
申请人:MERCK & CO INC
公开号:WO2010014453A1
公开(公告)日:2010-02-04
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
[EN] CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS<br/>[FR] CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES EN TANT QU'INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2013040863A1
公开(公告)日:2013-03-28
Cycloalkylnitrile pyrazole carboxamides as JAK inhibitors useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer are provided.